1. Dong L, Zhan GX, WU DZ. Inhibition of dimethyl hydrazine (DMH) induced colorectal cancer in rats by JinFuKang. Chin Tradit Patent Med. 2007;29(7):1061–3.
2. Qiu YP, Su MM, WU DZ, Zhao AH, Liu YM, Jia W. Effect of JinFuKang to experimental precancerous colon lesions and urinary metabolites in rat. China J Chin Mater Med. 2008;33(22):2653–7.
3. Liu JX, Pan MQ, Li YH, Ye DQ, Guo YH, Li YJ. Clinical study of oral liquid Jin Fu Kang for the treatment of primary non-small cell lung cancer. Tumor (Shanghai). 2001;21(6):463–5. This is one of the largest clinical trials on JinFuKang designed to evaluate the chemotherapeutic efficacy of JinFuKang in stage II/III NSCLC patients. This study showed that patients that received chemotherapy plus JinFuKang exhibited a higher response than chemotherapy alone. The symptoms, Karnofsky Performance Status (KPS), and immune parameters were improved, and the side effects of the chemotherapy were decreased.
4. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006;24(3):419–30. This study using meta-analysis on Astragalus-based Chinese herbs indicates that Astragalus may increase effectiveness of platinum-based chemotherapy in advanced NSCLC.
5. Li HG, Chen XH, Yao YL, Ren WL. A study of JinFuKang in the treatment of liver cancer. Chin Tradit Herb Drugs. 2000;31(7):533–5.